Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to apx-amoxicillin/clavulanic acid 875/125 tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to apx-amoxicillin/clavulanic acid 875/125 tablets should not require the addition of another antibiotic due to the amoxycillin content of apx-amoxicillin/clavulanic acid 875/125 tablets. short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam/muric tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam/muric tablets should not require the addition of another antibiotic due to the amoxycillin content of curam/muric tablets.

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amoxicillin; clavulanic acid - film-coated tablet - 500 mg/ 125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - : antibacterials for systemic use, combinations of penicillins, incl. beta-lactamase inhibitors - - acute bacterial sinusitis (adequately diagnosed) - acute otitis media - acute exacerbations of chronic bronchitis (adequately diagnosed) - community acquired pneumonia - cystitis - pyelonephritis - skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis. - bone and joint infections, in particular osteomyelitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate; clavulanic acid (as potassium clavulanate, diluted with microcrystalline cellulose (1:1)) - film-coated tablet - 500/125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor - combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility apx-amoxicillin/clavulanic acid 500/125 tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to apx-amoxicillin/clavulanic acid 500/125 tablets should not require the addition of another antibiotic due to the amoxycillin content of apx-amoxicillin/clavulanic acid 500/125 tablets.

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 400 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for oral suspensi

United States - English - NLM (National Library of Medicine)

sandoz inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), amoxicillin sodium (unii: 544y3d6myh) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 562.5 mg - amoxicillin and clavulanate potassium extended-release tablets is indicated for the treatment of infections in adults and pediatric patients with due to confirmed, or suspected β-lactamase-producing pathogens (i.e., h. influenzae, m. catarrhalis, h. parainfluenzae, k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin mics equal to 2 mcg/ml). limitations of use amoxicillin and clavulanate potassium extended-release tablets is not indicated for the treatment of infections due to s. pneumoniae with penicillin mics greater than or equal to 4 mcg/ml. data are limited with regard to infections due to s. pneumoniae with penicillin mics greater than or equal to 4 mcg/ml [see clinical studies (14)] . usage to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium extended-release tablets and other antibacterial drugs, amoxicillin and clavulanate potassium extended-releas

United States - English - NLM (National Library of Medicine)

putney, inc. - amoxicillin anhydrous (unii: 9em05410q9) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 50 mg - indications: amoxicillin trihydrate and clavulanate potassium tablets are indicated in the treatment of: dogs: skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus , non-β-lactamase-producing staphylococcus aureus , staphylococcus spp., streptococcus spp., and e. coli . periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. amoxicillin trihydrate and clavulanate potassium tablets have been shown to be clinically effective for treating cases of canine periodontal disease. cats: skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing staphylococcus aureus , non-β-lactamase-producing staphylococcus aureus , staphylococcus spp., streptococcus spp., e. coli , and pasteurella spp. urinary tract infections (cystitis)

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate ; clavulanic acid (as potassium clavulanate, diluted with microcrystalline cellulose (1:1)) - film coated tablet - 875/125 milligram - amoxicillin and enzyme inhibitor - : combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillin trihydrate ; clavulanic acid (as potassium clavulanate, diluted : cellulose, microcrystalline(1:1)) - film coated tablet - 500/125 milligram - amoxicillin and enzyme inhibitor - : combination of penicillins, incl. beta-lactamase inhibitors - acute bacterial sinusitis (adequately diagnosed) acute otitis media acute exacerbations of chronic bronchitis (adequately diagnosed) community acquired pneumonia cystitis pyelonephritis skin and soft tissue infections in particular cellulitis, animal bites and severe dental abscess with spreading cellulitis. bone and joint infections, in particular osteomyelitis

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), amoxicillin sodium (unii: 544y3d6myh) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 562.5 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium extended release tablets and other antibacterial drugs, amoxicillin and clavulanate potassium extended release tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium extended release tablets is indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase–producing pathogens (i.e., h. influenzae , m. catarrhalis , h. parainfluenzae , k. pneumoniae , or methicillin-susceptible s. aureus ) and s. pneumoniae with reduced susceptibility to penic